Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
21.46
-0.28 (-1.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACADIA Pharmaceuticals Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
18
19
Next >
3 Nasdaq Stocks on Watch This Week
↗
March 12, 2023
These three Nasdaq stocks are poised to make big moves in the coming week.
Via
The Motley Fool
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
March 10, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
1 Top Biotech Stock to Buy in March
↗
March 07, 2023
This biotech could land a major regulatory approval this month.
Via
The Motley Fool
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
March 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed
↗
March 02, 2023
Via
Benzinga
Analysts See Steady Growth For Acadia Pharma's Nuplazid
↗
February 28, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
↗
February 28, 2023
Via
Benzinga
Earnings Preview For ACADIA Pharmaceuticals
↗
February 24, 2023
Via
Benzinga
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
February 27, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 14, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
January 09, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
↗
December 21, 2022
Via
Benzinga
Earnings Scheduled For February 27, 2023
↗
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Analyst Expectations for ACADIA Pharmaceuticals's Future
↗
January 31, 2023
Via
Benzinga
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
January 03, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
December 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
November 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Trofinetide Phase III Clinical Top-Line Results Positive
November 16, 2022
Via
AB Newswire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
↗
November 04, 2022
Upgrades
Via
Benzinga
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
↗
November 01, 2022
Upgrades
Via
Benzinga
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
October 31, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 27, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 20, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 13, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
October 04, 2022
From
Acadia Pharmaceuticals
Via
Business Wire
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
↗
September 12, 2022
Via
Benzinga
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
↗
September 12, 2022
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
